本文選題：胃癌 + 腫瘤標(biāo)志物��； 參考：《中國(guó)腫瘤臨床》2017年07期

【摘要】：目的:探討聯(lián)合檢測(cè)術(shù)前、術(shù)后CEA、CA19-9、CA72-4等腫瘤標(biāo)志物對(duì)不同分期胃癌根治術(shù)后復(fù)發(fā)的預(yù)測(cè)價(jià)值。方法:回顧性分析北京大學(xué)腫瘤醫(yī)院2002年1月至2007年3月收治的564例胃癌患者的臨床資料及血清腫瘤標(biāo)志物情況。所有患者均未行新輔助治療,術(shù)前、術(shù)后均聯(lián)合檢測(cè)CEA、CA19-9、CA72-4等腫瘤標(biāo)志物。分析CEA、CA19-9、CA72-4等腫瘤標(biāo)志物與胃癌復(fù)發(fā)的關(guān)系。結(jié)果:在Ⅰ、Ⅱ期胃癌患者中,CEA、CA19-9、CA72-4術(shù)前陽(yáng)性的患者術(shù)后復(fù)發(fā)率分別為50.0%、24.1%、22.6%,而術(shù)后陽(yáng)性的患者復(fù)發(fā)率分別為42.9%、21.7%、14.3%。在Ⅲ期胃癌患者中,CEA、CA19-9、CA72-4術(shù)前陽(yáng)性的患者術(shù)后復(fù)發(fā)率分別為50.0%、55.2%、47.6%,而術(shù)后陽(yáng)性的患者術(shù)后復(fù)發(fā)率分別為75.0%、66.7%、66.7%。多因素分析表明術(shù)前CEA增高是Ⅰ、Ⅱ期胃癌復(fù)發(fā)的獨(dú)立影響因素,術(shù)后CA72-4增高是Ⅲ期胃癌復(fù)發(fā)的獨(dú)立影響因素。結(jié)論:對(duì)于Ⅰ、Ⅱ期胃癌,術(shù)前CEA水平是預(yù)測(cè)復(fù)發(fā)較好的因子;對(duì)于Ⅲ期胃癌,術(shù)后CA72-4水平的預(yù)測(cè)性較好。
[Abstract]:Objective: to evaluate the value of combined detection of preoperative and postoperative tumor markers such as CA19-9 and CA72-4 in predicting the recurrence of gastric cancer after radical resection with different stages. Methods: the clinical data and serum tumor markers of 564 patients with gastric cancer admitted to Peking University Cancer Hospital from January 2002 to March 2007 were retrospectively analyzed. All the patients were not treated with neoadjuvant therapy. The tumor markers such as CA19-9 and CA72-4 were detected before and after operation. To analyze the relationship between tumor markers such as CA19-9, CA72-4 and recurrence of gastric cancer. Results: among the patients with stage 鈪，

本文編號(hào)：1792569